Lars Bo Nielsen is stepping down as director of the Danish Medicines Agency after taking on a new job. Lars Bo Nielsen, who has led the agency since 2021, will resign from his position at the end of July. The Danish Medicines Agency announced his resignation in a press release, stating that Nielsen has accepted a new job. Technical director Mette Aaboe Hansen will temporarily take over the role as director from August 1 until a permanent successor is found, the agency reports.
In the press release, Minister of Interior and Health Sophie Løhde praised Lars Bo Nielsen for his remarkable work. She highlights that he has strengthened the Danish Medicines Agency’s position in European drug cooperation and put Denmark on the map in terms of developing new drugs, supply security, and the Life Science industry. Lars Bo Nielsen has played a central role in bringing scientific and technological advancements in living organisms to the forefront, which is essential for addressing health and societal challenges globally.
Mette Aaboe Hansen, who will lead the Danish Medicines Agency in the interim, has previously held several leadership positions within the organization, most recently as technical director of the Center for Drug Approval and Monitoring. She is a trained lawyer. The Danish Medicines Agency has not yet disclosed the position Lars Bo Nielsen has obtained, but announces that his current position will soon be advertised.